DA-9501

Phase 3Small molecule

Pfizer

DA-9501 is one of 5 small molecule programs targeting Medical Procedure. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Medical ProcedureActive, not recruiting

Medical ProcedurePhase 3

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Medical Procedure

#DrugCompanyPhaseTrials

Anerem

AAcacia Pharma Ltd

Phase 3

1 2

DA-9501

Pfizer

Phase 3

1 3

Voltaren

Novartis

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 5

Calcium Hydroxide

MMansoura University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Medical Procedure1 trial

Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery or Medical Procedure Without Intubation

Completed· Pfizer logo

Pfizer·Phase 3·NCT01438931·162 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DA-9501. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DA-9501 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DA-9501. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

DA-9501

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Medical Procedure1 trial

References

Drug Info

Quick Facts

Related News